P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL

ABSTRACT:

SUBMITTER: Mai E 

PROVIDER: S-EPMC9429267 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature